Erythropoietin Modification Enhances the Protection of Mesenchymal Stem Cells on Diabetic Rat-Derived Schwann Cells: Implications for Diabetic Neuropathy
- PMID: 28299330
- PMCID: PMC5337339
- DOI: 10.1155/2017/6352858
Erythropoietin Modification Enhances the Protection of Mesenchymal Stem Cells on Diabetic Rat-Derived Schwann Cells: Implications for Diabetic Neuropathy
Abstract
Diabetes-triggered apoptosis of Schwann cells (SC) contributes to the degradation of diabetic peripheral neuropathy (DNP). In recent years, mesenchymal stem cells (MSC) were applied to DPN repair and it was demonstrated that paracrine secretion played a key role in neuroprotection exerted by MSC. Erythropoietin (EPO) is a potent cytokine capable of reducing apoptosis of SC. However, the expression of EPO in MSC is limited. In this study, we hypothesized that overexpression of EPO in MSC (EPO-MSC) may significantly improve their neuroprotective potentials. The EPO overexpression in MSC was achieved by lentivirus transduction. SC derived from the periphery nerve of diabetic rats were cocultured with MSC or EPO-MSC in normal or high glucose culture condition, respectively. In normal glucose culture condition, the overexpression of EPO in MSC promoted the MSC-induced restoration of SC from diabetic rats, including increases in GSH level and cell viability, decrease in TUNEL apoptosis, upregulation of antiapoptotic proteins, p-Akt, and Bcl-2, and downregulation of proapoptotic proteins, cleaved caspase-3, and Bax. The subsequent results in high glucose culture condition showed similar promotions achieved by EPO-MSC. Thus, it could be concluded that EPO-MSC possessed a potent potential in hampering apoptosis of SC, and the suppression was probably attributed to attenuating oxidative stress and regulating apoptosis related protein factors.
Conflict of interest statement
The authors declare that there is no conflict of interests regarding the publication of this paper.
Figures
Similar articles
-
Erythropoietin attenuates oxidative stress and apoptosis in Schwann cells isolated from streptozotocin-induced diabetic rats.J Pharm Pharmacol. 2014 Aug;66(8):1150-60. doi: 10.1111/jphp.12244. Epub 2014 Mar 27. J Pharm Pharmacol. 2014. PMID: 24673486
-
Hypoxia pretreatment and EPO-modification enhance the protective effects of MSC on neuron-like PC12 cells in a similar way.Biochem Biophys Res Commun. 2017 Jan 8;482(2):232-238. doi: 10.1016/j.bbrc.2016.11.046. Epub 2016 Nov 11. Biochem Biophys Res Commun. 2017. PMID: 27845038
-
ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD.Invest Ophthalmol Vis Sci. 2010 Jan;51(1):35-46. doi: 10.1167/iovs.09-3544. Epub 2009 Jul 23. Invest Ophthalmol Vis Sci. 2010. PMID: 19628748
-
Erythropoietin: A potential drug in the management of diabetic neuropathy.Biomed Pharmacother. 2018 Sep;105:956-961. doi: 10.1016/j.biopha.2018.06.068. Epub 2018 Jun 19. Biomed Pharmacother. 2018. PMID: 30021390 Review.
-
Endogenous Erythropoietin.Vitam Horm. 2017;105:39-56. doi: 10.1016/bs.vh.2017.03.003. Epub 2017 May 18. Vitam Horm. 2017. PMID: 28629524 Review.
Cited by
-
Mesenchymal stem cell-derived extracellular vesicles promote apoptosis in RSC96 Schwann cells through the activation of the ERK pathway.Int J Clin Exp Pathol. 2018 Nov 1;11(11):5157-5170. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31949596 Free PMC article.
-
Perspectives on Stem Cell Therapy in Diabetic Neuropathic Pain.Neurol Int. 2024 Aug 30;16(5):933-944. doi: 10.3390/neurolint16050070. Neurol Int. 2024. PMID: 39311343 Free PMC article. Review.
References
-
- Magnani P., Thomas T. P., Tennekoon G., DeVries G. H., Greene D. A., Brosius F. C., III Regulation of glucose transport in cultured schwann cells. Journal of the Peripheral Nervous System. 1998;3(1):28–36. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials